Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 25,111 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 25,111 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total value of $691,808.05. Following the completion of the transaction, the insider directly owned 313,964 shares in the company, valued at approximately $8,649,708.20. The trade was a 7.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $0.86 during mid-day trading on Thursday, hitting $31.95. 18,861,192 shares of the company were exchanged, compared to its average volume of 26,241,924. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The stock has a 50 day simple moving average of $32.17 and a 200-day simple moving average of $26.05. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $65.30. The firm has a market cap of $7.45 billion, a price-to-earnings ratio of -50.71 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s quarterly revenue was up 38.2% on a year-over-year basis. During the same quarter last year, the business earned $0.17 earnings per share. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post -0.05 EPS for the current fiscal year.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum rejected the FTC’s allegations concerning data privacy, advertising, billing and subscription cancellations, arguing that the agency misunderstands Hims & Hers’ business practices. His comments may be helping ease concerns after the recent regulatory-driven selloff. Hims & Hers rejects privacy allegations
• Positive Sentiment: Analysts remain focused on Hims & Hers’ growth potential, including margin expansion and broader access to care. A recent investment thesis characterized the current margin pressure as a potential buying opportunity, while the CEO said an AI health coach could launch within roughly 12 months and potentially improve medication adherence. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Management’s planned expansion into AI-enabled care, testosterone and peptide treatments could create new growth avenues, but these initiatives remain prospective and do not immediately resolve regulatory or profitability concerns.
• Negative Sentiment: The FTC lawsuit remains the central overhang. It alleges improper handling of private health data and potentially deceptive billing and cancellation practices. Multiple law firms, including Kaplan Fox, Berger Montague and Kessler Topaz, have announced investigations that could increase legal costs, compliance requirements and potential securities-liability exposure. Kaplan Fox investigation
• Negative Sentiment: Recent earnings showed strong revenue growth of 38.2% year over year and revenue above expectations, but the company posted a substantially larger-than-expected loss. The $0.37 adjusted loss per share versus a $0.05 consensus loss highlights investor concerns about margins and execution.
• Negative Sentiment: Several executives reported stock dispositions, including sales by the CEO, CFO and CTO. Most were nondiscretionary share withholdings or sales under Rule 10b5-1 plans to cover taxes on vested equity, limiting their value as a confidence signal but still adding a modest supply-related overhang. SEC insider transaction filing

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB grew its stake in shares of Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares during the period. Sigma Planning Corp lifted its stake in shares of Hims & Hers Health by 1.5% in the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock valued at $540,000 after purchasing an additional 388 shares during the period. Captrust Financial Advisors lifted its stake in shares of Hims & Hers Health by 3.1% in the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock valued at $728,000 after purchasing an additional 443 shares during the period. Binnacle Investments Inc purchased a new stake in Hims & Hers Health during the third quarter worth about $28,000. Finally, Northwestern Mutual Investment Management Company LLC boosted its holdings in Hims & Hers Health by 1.1% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 46,607 shares of the company’s stock worth $1,513,000 after buying an additional 521 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Barclays boosted their price target on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 17th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research report on Friday, May 22nd. BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a report on Tuesday, May 12th. Finally, Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $32.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.